logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Figure INF-9. Prevalence of markers of HBV infection among injecting drug users - studies with national and subnational coverage [see all figures in this series...]

Part (ii) Percentage with current infection (positive for HBsAg), 2008 to 2009


Dark squares are samples with national coverage; blue triangle are samples with subnational (including local or regional) coverage.

Differences between countries have to be interpreted with caution owing to different types of settings and/or study methods; national sampling strategies vary.

Part of data from Portugal include non-IDUs and therefore may underestimate prevalence among IDUs (estimated proportion of non-IDUs in the samples not known).

Data for Portugal and Cyprus are limited to prevalence among IDUs in treatment and may not be representative of prevalence among IDUs who are not in treatment.

Countries are presented by order of increasing prevalence, based on the average of national data or, if not available, of subnational data.


Related links:

Statistical bulletin 2010: Figure INF-09 part (i)

For primary sources, study details and data before 2008, see Table INF-114 and Table INF-0.

See also ‘General notes for interpreting data’ on the Explanatory notes and help page.


Reitox national focal points

(see the help page for information about formats etc.)

Page last updated: Tuesday, 02 August 2011